Search results
Results from the WOW.Com Content Network
Metformin, sold under the brand name Glucophage, among others, is the main first-line medication for the treatment of Type 2 diabetes, [14] [15] [16] [17 ...
[4] [5] It is a combination of dapagliflozin and metformin [4] and is taken by mouth. [4] Dapagliflozin/metformin was approved for use in the European Union in January 2014, [ 3 ] in the United States in February 2014, [ 5 ] [ 6 ] and in Australia in July 2014.
The fixed-dose combination product, dapagliflozin/metformin extended-release, is called Xigduo XR. [ 55 ] [ 56 ] [ 57 ] In July 2016, the fixed-dose combination of saxagliptin and dapagliflozin was approved for medical use in the European Union and is sold under the brand name Qtern. [ 58 ]
SGLT2 inhibitor. SGLT2 inhibitors (also called gliflozins or flozins) are a class of medications that inhibit sodium-glucose transport proteins in the nephron (the functional units of the kidney), unlike SGLT1 inhibitors that perform a similar function in the intestinal mucosa. The foremost metabolic effect of this is to inhibit reabsorption of ...
To reduce the risk of developing ketoacidosis (a serious condition where the body produces high levels of blood acids called ketones) after surgery, the FDA has approved changes to the prescribing information for SGLT2 inhibitor diabetes medications, recommending they be temporarily stopped before scheduled surgery.
In the United States, sitagliptin/metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. [5] [6]In the European Union, sitagliptin/metformin is indicated as an adjunct to diet and exercise to improve glycemic control in people with type 2 diabetes; in combination with a sulfonylurea as an adjunct to diet and exercise "in people ...
to improve glycemic control when metformin with or without sulphonylurea (SU) and either saxagliptin or dapagliflozin does not provide adequate glycemic control. when already being treated with metformin and saxagliptin and dapagliflozin. References
Typical reduction in glycated hemoglobin (A1C) values for Metformin is 1.5–2.0% Metformin (Glucophage) may be the best choice for patients who also have heart failure, [10] but it should be temporarily discontinued before any radiographic procedure involving intravenous iodinated contrast, as patients are at an increased risk of lactic acidosis.